MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,818.93
+0.58%
NASDAQ 100
$31,224.47
+0.48%
DOW JONES
$51,521.00
+0.49%
NASDAQ Composite
$27,599.79
+0.45%
RUSSELL 2000
$2,813.40
-0.72%
CBOE VIX
$15.01
-3.29%
Sector Heatmap
Technology+0.53%
Financials+0.24%
Healthcare-0.17%
Consumer Cycl+1.20%
Consumer Staples+0.90%
Energy+0.47%
Industrials+0.87%
Materials+0.46%
Real Estate+1.06%
Utilities+2.98%
Comm Services+0.04%
NVAX — Novavax Inc
NasdaqNovavax Inc
$11.32
-1.24(-9.87%)
- O
- 12.35
- H
- 13.33
- L
- 10.88
- V
- 19.35M
⏱️ End-of-day dataAs of Oct 6, 2026
Chart
About NVAX
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateDec 5, 1995
Employees749
Stock ExchangeNasdaq
Ticker SymbolNVAX
Websitehttps://www.novavax.com
Key Financial Statistics
| Market Cap | $1.73B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $6.20 - $13.39 |
| 52-Week Avg Volume | 4.72M |
| VWAP | $11.68 |
| Transactions | 119,850 |
| Total Recorded Bars | 7,758 days |